This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fujii, S. Articles by Sobel, B. E. Search for Related Content PubMed PubMed Citation Articles by Fujii, S. Articles by Sobel, B. E.

Circulation, Vol 83, 645-651, Copyright © 1991 by American Heart Association

ARTICLES

Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis

S Fujii, WE Hopkins and BE Sobel
Cardiovascular Division, Washington University School of Medicine, St. Louis, MO 63110.

We recently hypothesized that after pharmacologically induced coronary thrombolysis, increased activity of plasminogen activator inhibitor type 1 (PAI-1) retards recanalization, contributes to early reocclusion, or both. This hypothesis was based on the increased elaboration of PAI-1 that we observed in cultured liver cells exposed to growth factors releasable from platelets activated at sites of thrombosis in vivo. PAI-1 released locally is particularly likely to attenuate lysis of thrombi that are targets of thrombolytic drugs. Accordingly, the present study was performed to determine whether synthesis of PAI-1 by endothelial cells is augmented by products of platelets. Lysates from platelets (0.5-8.0 x 10(4)/mm3 media, i.e. less than 10% of the concentration of platelets in blood) increased synthesis and release of PAI-1 into both the extracellular matrix and conditioned media (by 2.8-fold and 3.3-fold within 6 and 24 hours, respectively). Synthesis of neither tissue-type plasminogen activator nor overall protein increased. Increased synthesis of PAI-1 was confirmed by immunoprecipitation of [35S]PAI-1 after metabolic labeling of cells. The increased elaboration of PAI-1 was consistent with increased transcription as reflected by the observed increase in PAI-1 mRNA of 2.2-fold in 4 hours. Effects of platelet lysates were simulated by transforming growth factor beta (TGF-beta), known to be present in platelet alpha-granules and released with platelet activation. Antibody to TGF-beta reduced the stimulation of PAI-1 synthesis by TGF-beta, as expected, by 82%.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				J.-C. Murciano, D. Harshaw, D. G. Neschis, L. Koniaris, K. Bdeir, S. Medinilla, A. B. Fisher, M. A. Golden, D. B. Cines, M. T. Nakada, et al. Platelets inhibit the lysis of pulmonary microemboli Am J Physiol Lung Cell Mol Physiol, March 1, 2002; 282(3): L529 - L539. [Abstract] [Full Text] [PDF]

				P. E. Morange, M. C. Alessi, M. Verdier, D. Casanova, G. Magalon, and I. Juhan-Vague PAI-1 Produced Ex Vivo by Human Adipose Tissue Is Relevant to PAI-1 Blood Level Arterioscler Thromb Vasc Biol, May 1, 1999; 19(5): 1361 - 1365. [Abstract] [Full Text] [PDF]

				I. M. Lang, K. M. Moser, and R. R. Schleef Elevated Expression of Urokinase-like Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 During the Vascular Remodeling Associated With Pulmonary Thromboembolism Arterioscler Thromb Vasc Biol, May 1, 1998; 18(5): 808 - 815. [Abstract] [Full Text] [PDF]

				C. H. Lundgren, S. L. Brown, T. K. Nordt, B. E. Sobel, and S. Fujii Elaboration of Type-1 Plasminogen Activator Inhibitor From Adipocytes : A Potential Pathogenetic Link Between Obesity and Cardiovascular Disease Circulation, January 1, 1996; 93(1): 106 - 110. [Abstract] [Full Text]

				S. L. Brown, B. E. Sobel, and S. Fujii Attenuation of the Synthesis of Plasminogen Activator Inhibitor Type 1 by Niacin : A Potential Link Between Lipid Lowering and Fibrinolysis Circulation, August 15, 1995; 92(4): 767 - 772. [Abstract] [Full Text]

				P. B. Kurnik Circadian Variation in the Efficacy of Tissue-Type Plasminogen Activator Circulation, March 1, 1995; 91(5): 1341 - 1346. [Abstract] [Full Text]